Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.75 |
| ▸ | RAB9A | P51151 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | XBP1 | P17861 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21652312 | 1.00 | TRPV1 (0.76) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1687868 | 1.00 | TRPV1 (0.76) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7303163 | 0.91 | HDAC3 (0.86) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28329529 | 0.89 | SIRT1 (0.61) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28563049 | 0.87 | TRPV1 (0.59) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10684470 | 0.87 | PTPN1 (0.88) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23352870 | 0.87 | TRPV1 (0.67) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5222902 | 0.86 | NR1H4 (0.67) | TRPV1MEN1KMT2ANR1H4 | |
| SCHEMBL9179385 | 0.85 | PTPN1 (0.67) | TRPV1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL28330757 | 0.85 | SIRT1 (0.64) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| EP-0358118-B1 | Phenylamides - process for their preparation as well as a drug containing those compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-16 | — | — | EP | disclosed |
| US-5135949-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0358118-A1 | Phenylamides - process for their preparation as well as a drug containing those compounds | Roche Diagnostics GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | TRPV1 75/4885NPC1 1085/4885RAB9A 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.